BioSpace News Archive

ViewRay, Inc. announced that the Company will participate in the Jefferies 2019 Global Healthcare Conference in New York, New York.

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.

Lannett Company, Inc. announced that it has begun marketing a generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine tablet product, with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg tablets.

Medicenna Therapeutics Corp. announced that Dr. Dina Randazzo of Duke University, will present updates related to the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 31 to June 4, 2019 in Chicago, Illinois.

New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months

ALX Oncology announced that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.

Spectrum Pharmaceuticals announced that an overview of the company’s business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA.

Verastem, Inc. announced that the Company will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA.

Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data

Foundation Medicine, Inc. today announced that new data informed by the use of its portfolio of comprehensive genomic profiling (CGP) tests will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4 in Chicago.